Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
NUCC-390 is a chemokine (C-X-C motif) receptor 4 (CXCR4) agonist.1 It induces calcium mobilization in C8161 melanoma cells expressing CXCR4 when used at a concentration of 10 µM, an effect that can be prevented by the CXCR4 antagonist AMD3100 (plerixafor; Item No. 10011332). NUCC-390 (0.0625, 0.125, and 0.25 µM) increases axon length in cultured rat spinal cord motor neurons.2 In vivo, NUCC-390 (26 mg/kg per day) restores gastrocnemius muscle compound muscle action potentials (CMAPs) in a mouse model of sciatic nerve crush injury. It also restores CMAPs in a mouse model of neuroparalysis induced by Papuan taipan (O. scutellatus) venom.3
WARNING This product is not for human or veterinary use.
1. Discovery and characterization of novel small-
2. A CXCR4 receptor agonist strongly stimulates axonal regeneration after damage. Ann. Clin. Transl. Neurol. 6(12), 2395-2402 (2019).
3. An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation. PLoS Negl. Trop. Dis. 14(9), e0008547 (2020).